CR20200241A - Ligandos de psma para la formación de imágenes y endoradioterapia - Google Patents
Ligandos de psma para la formación de imágenes y endoradioterapiaInfo
- Publication number
- CR20200241A CR20200241A CR20200241A CR20200241A CR20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A
- Authority
- CR
- Costa Rica
- Prior art keywords
- psma
- imaging
- endoradiotherapy
- links
- compounds
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title abstract 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title abstract 4
- 238000003384 imaging method Methods 0.000 title abstract 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000163 radioactive labelling Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. También se porporcionan usos médicos de dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17206510 | 2017-12-11 | ||
| PCT/EP2018/084399 WO2019115547A1 (en) | 2017-12-11 | 2018-12-11 | Psma ligands for imaging and endoradiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200241A true CR20200241A (es) | 2020-09-21 |
Family
ID=60654872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200241A CR20200241A (es) | 2017-12-11 | 2018-12-11 | Ligandos de psma para la formación de imágenes y endoradioterapia |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US11497819B2 (es) |
| EP (3) | EP3723815B1 (es) |
| JP (3) | JP7317375B2 (es) |
| KR (1) | KR20200097690A (es) |
| CN (2) | CN116617421A (es) |
| AU (1) | AU2018382479B2 (es) |
| BR (1) | BR112020011727A2 (es) |
| CA (1) | CA3078104A1 (es) |
| CL (1) | CL2020001542A1 (es) |
| CR (1) | CR20200241A (es) |
| CU (1) | CU24677B1 (es) |
| DK (2) | DK4008359T3 (es) |
| EC (1) | ECSP20029142A (es) |
| ES (1) | ES2914832T3 (es) |
| FI (1) | FI4008359T3 (es) |
| HR (2) | HRP20220764T1 (es) |
| HU (1) | HUE059083T2 (es) |
| IL (2) | IL313103A (es) |
| JO (1) | JOP20200135A1 (es) |
| LT (2) | LT3723815T (es) |
| MX (2) | MX2020005430A (es) |
| PE (1) | PE20210456A1 (es) |
| PL (1) | PL3723815T3 (es) |
| PT (2) | PT4008359T (es) |
| RS (2) | RS63279B1 (es) |
| SG (1) | SG11202002965WA (es) |
| SI (1) | SI3723815T1 (es) |
| SM (1) | SMT202400439T1 (es) |
| TN (1) | TN2020000072A1 (es) |
| UA (1) | UA126413C2 (es) |
| WO (1) | WO2019115547A1 (es) |
| ZA (1) | ZA202003472B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313103A (en) | 2017-12-11 | 2024-07-01 | Univ Muenchen Tech | PSMA ligands for imaging and endoradiotherapy |
| MX2021008809A (es) | 2019-01-30 | 2021-11-12 | Univ Muenchen Tech | Agentes de imagenes de diagnostico del cancer. |
| HUE063038T2 (hu) * | 2019-01-30 | 2023-12-28 | Univ Muenchen Tech | Kettõs üzemmódú PSMA-kötõ radionyomjelzõk és terápiás szerek |
| JP7618599B2 (ja) | 2019-06-21 | 2025-01-21 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | 前立腺特異的膜抗原を標的とする放射性標識化合物 |
| CN112321673B (zh) * | 2020-11-04 | 2022-09-20 | 北京市肿瘤防治研究所 | 一种前列腺特异性膜抗原靶向抑制剂及应用和探针 |
| CN113354707A (zh) * | 2021-06-07 | 2021-09-07 | 苏州思萃同位素技术研究所有限公司 | 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品 |
| WO2023173074A2 (en) * | 2022-03-10 | 2023-09-14 | The Research Foundation For The State University Of New York | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| AU2009276423B2 (en) * | 2008-08-01 | 2014-10-30 | The Johns Hopkins University | PSMA-binding agents and uses thereof |
| WO2010135431A2 (en) * | 2009-05-19 | 2010-11-25 | The Regents Of The University Of California | Compositions, devices, and methods related to prostate-specific membrane antigen |
| EP4095130B1 (en) * | 2013-10-18 | 2024-01-31 | Novartis AG | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3140282B1 (en) | 2014-05-06 | 2019-07-10 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| PL3925952T3 (pl) * | 2016-03-22 | 2024-04-22 | The Johns Hopkins University | Środki o wysokim powinowactwie ukierunkowane na antygen błonowy swoisty dla gruczołu krokowego do endoradioterapii raka gruczołu krokowego |
| IL313103A (en) | 2017-12-11 | 2024-07-01 | Univ Muenchen Tech | PSMA ligands for imaging and endoradiotherapy |
| CN111683934B (zh) | 2017-12-11 | 2024-01-23 | 赫尔森保健股份公司 | (r)-3-(1-(2,3-二氯-4-(吡嗪-2-基)苯基)-2,2,2-三氟乙基)-1-甲基-1-(1-甲基哌啶-4-基)脲的延胡索酸盐、制备方法及其用途 |
| TW201930265A (zh) | 2017-12-11 | 2019-08-01 | 西班牙商阿爾米雷爾有限公司 | 作為acc抑制劑的吡咯衍生物 |
-
2018
- 2018-12-11 IL IL313103A patent/IL313103A/en unknown
- 2018-12-11 CN CN202310801735.3A patent/CN116617421A/zh active Pending
- 2018-12-11 LT LTEPPCT/EP2018/084399T patent/LT3723815T/lt unknown
- 2018-12-11 LT LTEP21218180.4T patent/LT4008359T/lt unknown
- 2018-12-11 ES ES18812215T patent/ES2914832T3/es active Active
- 2018-12-11 PT PT212181804T patent/PT4008359T/pt unknown
- 2018-12-11 PL PL18812215.4T patent/PL3723815T3/pl unknown
- 2018-12-11 RS RS20220527A patent/RS63279B1/sr unknown
- 2018-12-11 RS RS20241176A patent/RS66086B1/sr unknown
- 2018-12-11 EP EP18812215.4A patent/EP3723815B1/en active Active
- 2018-12-11 DK DK21218180.4T patent/DK4008359T3/da active
- 2018-12-11 PT PT188122154T patent/PT3723815T/pt unknown
- 2018-12-11 JO JOP/2020/0135A patent/JOP20200135A1/ar unknown
- 2018-12-11 MX MX2020005430A patent/MX2020005430A/es unknown
- 2018-12-11 WO PCT/EP2018/084399 patent/WO2019115547A1/en active Application Filing
- 2018-12-11 HU HUE18812215A patent/HUE059083T2/hu unknown
- 2018-12-11 KR KR1020207014036A patent/KR20200097690A/ko not_active Application Discontinuation
- 2018-12-11 DK DK18812215.4T patent/DK3723815T3/da active
- 2018-12-11 US US16/765,729 patent/US11497819B2/en active Active
- 2018-12-11 HR HRP20220764TT patent/HRP20220764T1/hr unknown
- 2018-12-11 BR BR112020011727-7A patent/BR112020011727A2/pt unknown
- 2018-12-11 EP EP24198677.7A patent/EP4464341A3/en active Pending
- 2018-12-11 AU AU2018382479A patent/AU2018382479B2/en active Active
- 2018-12-11 SI SI201830691T patent/SI3723815T1/sl unknown
- 2018-12-11 HR HRP20241453TT patent/HRP20241453T1/hr unknown
- 2018-12-11 FI FIEP21218180.4T patent/FI4008359T3/fi active
- 2018-12-11 CU CU2020000052A patent/CU24677B1/es unknown
- 2018-12-11 IL IL274072A patent/IL274072B2/en unknown
- 2018-12-11 SG SG11202002965WA patent/SG11202002965WA/en unknown
- 2018-12-11 CA CA3078104A patent/CA3078104A1/en active Pending
- 2018-12-11 PE PE2020000552A patent/PE20210456A1/es unknown
- 2018-12-11 TN TNP/2020/000072A patent/TN2020000072A1/en unknown
- 2018-12-11 CN CN201880056196.2A patent/CN111182927B/zh active Active
- 2018-12-11 EP EP21218180.4A patent/EP4008359B1/en active Active
- 2018-12-11 JP JP2020526146A patent/JP7317375B2/ja active Active
- 2018-12-11 CR CR20200241A patent/CR20200241A/es unknown
- 2018-12-11 UA UAA202003533A patent/UA126413C2/uk unknown
- 2018-12-11 SM SM20240439T patent/SMT202400439T1/it unknown
-
2020
- 2020-06-03 EC ECSENADI202029142A patent/ECSP20029142A/es unknown
- 2020-06-10 ZA ZA2020/03472A patent/ZA202003472B/en unknown
- 2020-06-10 CL CL2020001542A patent/CL2020001542A1/es unknown
- 2020-07-13 MX MX2023005053A patent/MX2023005053A/es unknown
-
2022
- 2022-07-15 US US17/866,034 patent/US20230122957A1/en active Pending
-
2023
- 2023-07-11 JP JP2023113523A patent/JP7572080B2/ja active Active
-
2024
- 2024-10-03 JP JP2024173980A patent/JP2025011169A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20029142A (es) | Ligandos de psma para la formación de imágenes y endorradioterapia | |
| CL2017003021A1 (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| DOP2018000280A (es) | Compuestos moduladores de fxr (nr1h4) | |
| SV2018005684A (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CL2017001736A1 (es) | Anticuerpos anti-cd47 y uso de los mismos. | |
| PE20171041A1 (es) | Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
| ECSP21026339A (es) | Anticuerpos antihlag, composiciones que comprenden anticuerpos antihlag y métodos de uso de anticuerpos antihlag | |
| UY36757A (es) | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada | |
| CO2020012360A2 (es) | Anticuerpos multiespecíficos y utilización de los mismos | |
| PE20181367A1 (es) | Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso | |
| BR112016025470A2 (pt) | ?hdl terapêutico? | |
| MY194484A (en) | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer | |
| CR20130499A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| MX2017011194A (es) | Anticuerpos, usos y métodos. | |
| AR113543A2 (es) | Ésteres de oxaborol y sus usos | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| BR112016030291A2 (pt) | terapia de combinação | |
| AR117578A1 (es) | Anticuerpos específicos para cd3 y sus usos |